The lupus anticoagulant, an acquired circulating serum y-globulin, prolongs all phospholipid-dependent coagulation tests. Recent associations of the lupus anticoagulant and focal cerebral and/or ocular ischemia have been made. We present 5 cases of lupus anticoagulant-associated cerebrovascular ischemia and review all reported cases for the first time. Clinical spectra, cerebral angiographic findings, associated conditions, and response to therapy are presented. Typical features include a relatively young age (mean 39 years), female preponderance, transient ischemic attacks (including amaurosis fugax) or stroke, and normal or large vessel occlusions on angiography. Commonly associated conditions were systemic lupus erythematosus (34%), noncerebral venous thrombosis (31%), hypertension (28%), false-positive VDRL (28%), and spontaneous abortions (22% 38 and healthy children and adults. 20 We present 5 cases of LA-associated cerebrovascular disease. All reported patients are reviewed in an attempt to establish typical clinical and angiographic features, response to therapy, and associated conditions.
T HE presence of a lupus anticoagulant (LA), an acquired circulating serum y-globulin (IgG, IgM, or mixed), has been reported in patients with transient and permanent focal cerebral and/or ocular ischemia with or without systemic lupus erythematosus (SLE). M0 LA prolongs the partial thromboplastin time (PTT) by inhibiting the prothrombin complex" 12 and in vitro appears to act like an anticoagulant. 13 Paradoxically, in vivo, patients with LA seem to have an increased tendency for systemic and cerebrovascular thrombotic events, 14 " 16 possibly related in part to inhibition of vascular tissue prostacyclin I 2 production. 17 LA has been reported in association with SLE i.2.4-7.9.io..3.i4,i6,i8 p h e nothiazine use, 2310 autoimmune diseases, 2414 the puerperium, 8 stroke during pregnancy, 19 spontaneous abortions, 119 -32 thrombocytopenia, 2451014 a false-positive VDRL, 121014 neoplasia, 2410 ' 20 acquired immunodeficiency syndrome (AIDS), 38 and healthy children and adults. 20 We present 5 cases of LA-associated cerebrovascular disease. All reported patients are reviewed in an attempt to establish typical clinical and angiographic features, response to therapy, and associated conditions.
Case 1
A 41-year-old white man presented with multiple types of visual spells going back 20 years. Isolated vertical diplopia generally lasting 15 minutes occurred independently from abrupt tunnel vision with slow recovery in the left eye. The visual obscuration began from the periphery, moved centrally, resolved gradually, and left a transient wedge-shaped scotoma. These spells were accompanied in recent months by sudden onset of memory impairment and confusion lasting minutes. Several spells were accompanied by left lower facial numbness that spread to the left arm. Spells were never accompanied by a warning or headache. Fifteen years previously he suffered occasional spells of isolated vertigo lasting minutes, now occurring more frequently. He has also experienced episodes of intermittent arthralgias with joint .swelling, relieved with intermittent naproxen treatment. A previously noted false-positive VDRL had been extensively evaluated, including normal cerebrospinal fluid (CSF) findings. His past medical history was remarkable for 20 years of mild-to-moderate hypertension controlled with medication.
General physical, musculoskeletal, neurovascular (including carotid arteries), and neurological examinations were all normal. Blood pressure was 140/85 mm Hg. Immunologic and rheumatologic laboratory testing was normal. Hematologic profile is shown in Table  1 . Assays of coagulation factors IX and XI showed markedly reduced activity. Cholesterol and triglycerides, head computerized tomography (CT) with contrast infusion, magnetic resonance imaging, CSF, visual evoked responses, Holter cardiac monitor, and echocardiography were normal. EEG revealed only excessive bianterior dysrhythmia on hyperventilation. Cerebral arteriography was refused. Xenon-133 inhalation regional cerebral blood flow (rCBF) analysis was performed before and twice after therapy by meth- ods previously described. 21 There were areas of relatively low perfusion in the right occipital and left occipito-parietal cortices. Only the right occipital area of oligemia normalized after therapy. A diagnosis of LAassociated multifocal cerebro-ocular ischemia was made. The patient was placed on prednisone, aspirin, and dipyridamole. His transient cerebro-ocular symptoms persist, as does his LA.
Case 2
A 66-year-old man had multiple transient ischemic attacks (TIA's) involving left-sided weakness, primarily of the leg. Head CT was negative. Four years later he had several episodes of right-sided weakness and paresthesia. A very mild right hemiparesis was present. Head CT revealed small infarctions in the left frontal and parietal regions. He had also a false-positive VDRL, hypertensive nephropathy, hypertriglyceridemia, hyperuricemia, myocardial infarction (MI) with congestive heart failure, and a history of tobacco abuse. Hematologic profile is shown in Table 1 . Fibrinogen was elevated, and Westergren sedimentation rate was 82 mm/hr. Digital subtraction angiography (DSA) revealed only a high-grade stenosis of the left vertebral artery. On aspirin and dipyridamole therapy he remained asymptomatic for 1 year. Bilateral subclavian vein and left innominate vein thromboses were subsequently documented. He has continued on warfarin (Coumadin) without new cerebral events for 2 years.
Case 3
A 38-year-old man with a history of rheumatic heart disease, tobacco abuse, and hypertension developed SLE with a false-positive VDRL. Four years later he had impaired speech and left-sided paresthesia for 5 hours. He then had transient episodes of unilateral (primarily left) and bilateral loss of vision, occurring up to 5 times daily, lasting minutes, usually preceded or followed by a severe frontal headache and lightheadedness. Inferior vena cava ligation was performed for iliac vein thrombosis. Recurrent deep venous thrombosis had been documented. Neurologic examination and EEG were normal. Heparin was started. Cerebral arteriography revealed an ulcerated, nearly occluded left internal carotid artery (ICA). He had a left carotid endarterectomy and developed a postoperative carotid "pseudoaneurysm." Plasmapheresis was performed prior to aneurysm-carotid ligation. He was then placed on cyclophosphamide, prednisone, and aspirin. He continued with amaurotic episodes in the left eye and bilaterally, and was lost to followup after 3 years.
Case 4
A 63-year-old woman with insulin-dependent diabetes mellitus, severe peripheral vascular occlusive disease, and congestive heart failure was hospitalized for increasing shortness of breath. She had a long history of hypertriglyceridemia, tobacco abuse, hemolytic anemia, and thrombocytopenia. She had undergone surgery for iliac artery occlusion and had had several peripheral arterial embolectomies. She was febrile and dyspneic, with bilateral carotid bruits. Pneumococcal pneumonia was diagnosed. She became progressively more lethargic and inattentive and displayed left-sided weakness. Examination was consistent with a large right middle cerebral artery (MCA) infarction. Head CT showed an early right parietal lucency. ECG showed an acute antero-septal injury pattern. Arteriography was not performed. Hematologic profile is shown in Table 1 . She was placed on aspirin and dipyridamole without further events during a 6-month followup.
Case 5
A 54-year-old woman with a history of rheumatic heart disease, hypothyroidism, tobacco abuse, "coagulopathy," and thrombocytopenia began experiencing left supraorbital headaches associated with left arm numbness and weakness lasting minutes. These were occasionally associated with blurry vision, black spots in her left visual field, lightheadedness, and speech difficulty. She had "thyroiditis" at age 13. Head CT revealed a right frontal infarct. Hematologic profile is shown in Table 1 . An elevated IgM level was found. Echocardiography was normal. She was placed on steroids. A second stroke appeared on head CT following another episode of headache and arm weakness.
Discussion
All our patients satisfied the criteria of Mueh et al, 2 Feinstein and Rapaport, 15 and the working party on acquired inhibitors of coagulation 22 for the presence of circulating LA. This includes 1) a PTT exceeding the normal range for the laboratory by at least 5 seconds; 2) PTT of a 1:1 mixture of the patient's plasma and normal plasma at least 5 seconds longer than the PTT of normal plasma; 3) reduced activity of at least two of those factors measured in one-stage PTT assays, namely, factors XII, XI, IX, and VII; 4) evidence that measured activity of one or more of the above mentioned clotting factors increased with increasing dilution of the patient's plasma in the assays; and 5) no evidence of another cause for the clotting abnormalities.
The only documented clues to the cause of the first Definite stroke risk factors (SRF's) are documented heart disease (recent MI, rheumatic heart disease, endocarditis, congestive heart failure), hypertension, diabetes mellitus, hypertriglyceridemia, polycythemia, and pregnancy; probable/ possible SRF's are use of oral contraceptives, mitral valve prolapse, classic migraine, cigarette abuse, puerperium, non-SLE autoimmune disease/vasculitis.
•Only 1 case without SLE (Reference 1, case 1) had neither definite nor probable/possible SRF's coexisting. Several patients had both definite and probable/possible SRF's coexisting.
patient's repeated multifocal cerebro-ocular ischemia symptoms included circulating LA, a false-positive VDRL, thrombocytopenia that was mild, and hypertension. Acephalgic complicated or classic migraine (migraine equivalent) could explain the symptoms and even the oligemia seen on rCBF analysis. However, it would not explain his false-positive VDRL or thrombocytopenia. rCBF studies showed focal oligemia in the right occipital area corresponding to his left visual field symptoms, with normal CT and neurologic examination. This suggests to us a more persistent cerebrovascular pathophysiology, possibly related to ongoing focal oligemia or hypometabolism of the type demonstrated in TLA patients by positron emission tomography (PET) scan. 23 Recurrent transient intravascular coagulation secondary to LA could explain these episodes. A previously noted association with thrombocytopenia and migraine has been made, with the conjecture that this represents a subgroup of migraine sufferers with an immunologic pathogenesis including circulating autoantibodies. 24 Migraine has also been reported in patients with LA. 25 Hypertension, which is not labile, is extremely unlikely to be the sole cause of his recurrent symptoms. He did not meet the criteria for SLE or other specific autoimmune diseases; however, he has only been followed for 2 years and may still develop a specific syndrome.
Our other 4 patients had multiple reasons (definite stroke risk factors) for their cerebral ischemia. Patient 2 had a previous MI, congestive heart failure, hypertension, and tobacco abuse. Patient 3 had hypertension, rheumatic heart disease, tobacco abuse, and an ulcerated plaque with 99% stenosis of his left ICA. Patient 4 had insulin-dependent diabetes mellitus, congestive heart failure, hypertriglyceridemia, and significant tobacco use. Patient 5 had rheumatic heart disease and tobacco abuse.
In 4 of our 5 cases, the presence of LA could, therefore, not be invoked as the sole factor in precipitating the cerebrovascular ischemia, but may have contributed.
We have also studied 2 patients with cerebral venous thrombosis documented angiographically and LA (manuscript submitted for publication): A 21-year-old woman and a 32-year-old man both suffered superior sagittal sinus thrombosis and improved with corticosteroids and anticoagulants. Neither had other contributing factors or extensive evaluation.
We have reviewed the literature (27 other well-documented cases) characterizing the clinical features, cerebral arteriography, associated conditions, and response to therapy in LA-associated cerebrovascular ischemia.
Patients with LA have presented with single or multiple cerebral infarctions, TIA's, and classic migraine.
1 " t6 " 1017i2J Head CT scans have been normal or shown single or multiple low-attenuation regions consistent with infarction.
136 " 8 Cerebral angiography has been normal or has shown proximal ICA or MCA branch occlusion or stenosis. 6~8 rCBF has not been previously reported. Response to therapy has been highly variable. Table 2 is a summary of the stroke risk factor profiles in patients with cerebrovascular ischemic symptoms and circulating LA. The age range of the 32 patients was 15-66 years (mean, 39 years) with 9 men and 23 women (1:2.5). Sixty-nine percent had strokes only, 12% had both strokes and TIA's, and 19% had TIA's only (Table 3) . About one-third (11 of 32) had a definite diagnosis of SLE; of these, 73% had only strokes. Twenty-one patients did not have definite SLE; 4 of these 21 (19%) had TIA's only, which is The most common associated conditions (when published) were SLE (34%), venous thrombosis (31%), hypertension (28%), false-positive VDRL (28%), spontaneous abortion (22%), elevated sedimentation rate (19%, 3 with SLE), and tobacco use (16%). Others are listed in Table 4 .
Results of 18 cerebral arteriograms in 14 patients are listed in Table 5 . Eighteen patients did not have published findings. Intraarterial angiography demonstrated MCA branch or trunk occlusion in 3 patients, ICA occlusion or thrombosis in 4, and vasculitis in 1. One patient had unilateral ICA occlusion and contralateral ICA stenosis. No pathologic condition was noted in 5 of the 15 arteriograms. Extracranial vessels by DSA were normal in 2 patients, complete ICA occlusion was demonstrated in 1 patient, and a high-grade vertebral artery stenosis in another.
Review of the literature revealed a highly variable response of patients' symptoms to therapy (Table 6 ). Unfortunately, in 10 of the 32 (31%), details of the therapy were not published. Several patients received more than one treatment, and they could appear in more than one group. Mean followup when published was 2.4 years. Seven patients received steroid therapy alone or in combination with other medications. Five of these patients continued to have cerebrovascular ischemic events (TIA's or infarction) while on steroids. One patient, followed for only 3 months and also on aspirin, remained asymptomatic. Followup was not published in one. Our review of the few available data tentatively suggests that symptoms may persist in spite of steroid therapy. Both aspirin and other antiplatelet agents were given as the only therapy to 5 patients. Two "responded well," 2 remained asymptomatic after 4 and 6 months of followup, and 1 followup was not published. Four received either aspirin or other antiplatelet agents. Five patients received anticoagulant therapy alone or in combination with other medication. One was lost to followup. One continued to have TIA's, including amaurosis fugax. Two remained 
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•Several patients had more than I associated condition. **3 of 6 with elevated sedimentation rate had SLE.
ASA, aspirin; AP, antiplatelet therapy; AC, anticoagulant therapy; IS, immunosuppressives; PP, plasmapheresis.
Overall average followup = 2.4 years when published. *Patients may have had more than 1 therapy during followup.
by guest on August 28, 2017 http://stroke.ahajournals.org/ Downloaded from asymptomatic after warfarin was initiated, while one required the addition of aspirin to abate symptoms. Gastineau and coworkers 10 found that in 53 patients with LA and any episode of thrombosis (including noncerebrovascular), 9 had sufficient followup to evaluate therapy. Seven patients treated with warfarin had no further thrombotic events with 6 months-7 years followup. One patient had thrombosis 1 year later on warfarin. One patient treated with aspirin and dipyridamole had no further thrombophlebitis 2 years later. Two patients had thrombosis while on corticosteroids. LA has been reported to disappear with steroid therapy, 1518 splenectomy, 15 plasmapheresis, 14 pulse immunosuppressive therapy, 14 or spontaneously. 26 Most of these reports are anecdotal. Corticosteroids may normalize the PTT and therefore mask the presence of LA. 28 Fisher and McGehee 27 reported 8 patients with lupus-inhibitor-associated cerebral ischemia (7 with infarctions and 1 with TIA). Their age range was 26-56 years (average, 41 years) with a male:female ratio of 1:3. All patients had a least one of the following: prolonged PTT, positive ANA, false-positive VDRL, history of deep vein thrombosis, or thrombocytopenia. Unfortunately, clinical data necessary for inclusion in Table 2 was not provided. None of their 4 patients treated with warfarin had a recurrent stroke.
Gastineau et al'° found 7 "carotid/cerebrovascular" arterial thromboses in 219 patients with LA (3%). Six of the 7 had SLE, with "all cerebral events" "independent of cerebral vasculitis." Glueck et al 28 found 8 of 18 patients with SLE and LA had "serious neurologic events" that "contributed to death directly in three." Three patients with and 2 without LA had carotid artery thrombosis. One patient in the series of Gastineau et al with SLE and LA had a retinal vein thrombosis 10 and a single retinal artery thrombosis was reported by Glueck et al. 28 Neither study provided clinical, head CT, or angiographic data that could be included in Table 2 . Similarly, Harris et al 29 reported 15 patients, 13 with SLE and 2 with automimmune "lupus-like" illness with clinical and/or radiographic evidence of cerebral infarction. All 15 had elevated anticardiolipin antibody (ACA) levels. Eleven patients proved positive for the presence of LA; 4 were untested. However, these 11 were not specifically identified in their table and therefore could not be incorporated into Table 2 . Of their 15 patients, 11 were women and 4 men, nearly a 3:1 ratio. Ages ranged from 29 to 56 years (mean, 39 years). Four had signs referable to the vertebro-basilar circulation, 6 had noncerebral vessel occlusions (large arterial or deep venous), 6 had thrombocytopenia, and 2 had recurrent abortions. Seven had associated vasculitis, 4 had migraines, and 4 had TIA's. They determined ACA titers in SLE patients with stroke, in elderly controls with stroke unassociated with an autoimmune disease, in SLE patients without stroke or venous thrombosis, and in normal controls. ACA levels were detected in 2 of the 25 elderly patients with stroke, in 14 of the 35 SLE patients without a history of cerebral infarction or venous thrombosis, and in none of the 30 normal controls. Preliminary evidence suggests that LA and ACA detected by solid-phase radioimmunoassay have the same or closely related antigenicities, and that LA is an antiphospholipid antibody. 29 " 32 There is also preliminary evidence that LA may be a heterogeneous group of circulating anticoagulants in vitro. 33 This may help explain the clinical heterogeneity seen and the variable responses to therapy.
LA has been associated with a false-positive VDRL 121014 11 About 5-10% of patients with SLE have LA, 19 and those patients have a higher incidence of systemic and cerebrovascular thrombotic events. 1428 Glueck et al 28 compared SLE patients with and without LA, finding that the latter group had a higher prevalance of venous and arterial thrombotic events, a probable shorter life span, and significantly reduced platelet counts and aggregation. Boey et al 14 found a strong association between a false-positive VDRL, thrombocytopenia, and thrombosis. Patients with SLE (11 of 32 in our review) have many reasons for cerebrovascular symptoms.
118 - 34 Mueh et al 2 reported 21 of 35 patients (60%) with LA had an autoimmune abnormality; a false-positive VDRL was seen in 6 of his 28 patients (21%) and in 35% of 188 patients in the series of Gastineau et al. 10 In our review, 9 of 32 (28%) had a false-positive VDRL with cerebrovascular symptoms. This suggests that a false-positive VDRL (specific anticardiolipin cross-reactivity) with LA does not increase the risk of cerebrovascular symptoms above the risk of LA alone.
Sixty-six percent of the patients with LA and cerebrovascular ischemia did not have definite SLE, whereas Schleider et al, 20 Elias and Eldor, 4 and Gastineau et al 10 found no evidence of SLE in 50% of patients with LA. This suggests that cerebrovascular ischemia in the presence of LA confers approximately a one-third chance of finding definite SLE.
Carreras and Vermylen 17 postulated prostacyclin inhibition as the prothrombotic mechanism of LA when they found that 8 of 14 patients with LA, 6 of whom had thrombosis, lacked PGI 2 formation. However, their one patient with TIA's did not have inhibition of PGI 2 . We did not perform this assay on our patients. Other documented mechanisms of action of LA include antiphospholipid activity, 9 "-29 " 32 prekallikrein inhibition, 32 changes in platelet activity and aggregation, 12151826 and reactivity with complex brain lipids such as sphingomyelin. 30 " 32 The fatty acid portion of the phospholipid molecule appears essential for its antigenicity , 32 Altered functional activity of antithrombin HI, 35 direct antibody-antigen interaction in the vascular wall, 9 inhibition of protein C activation, 36 and thrombomodulin inhibition 37 have also been demonstrated.
In one study a strong correlation between raised ACA titers and venous and arterial thrombosis has been demonstrated; 5 of 15 patients with the highest ACA titers had cerebral thrombosis without other predisposing factors. 30 ACA, possibly independent of LA but associated with it, in 50-70% of cases may actually be the cause of the increased thrombotic tendency. 30 " 32 The ACA titer by solid-phase radioimmunoassay or enzyme-linked immunosorbent assay (ELISA) may be a useful parameter of therapy in patients with cerebrovascular ischemia and LA. Further, the actual ACA titer may be predictive of the risk of thrombosis. 39 In conclusion: LA should be suspected in patients with cerebrovascular ischemia and a prolonged F I T without other cause. The presence of LA appears to increase the risk of cerebrovascular ischemic symptoms in patients who have associated potential risk factors for cerebral ischemia. 31 Of the two-thirds of the patients not having SLE, over half had other coexisting potential causes for stroke. It is still unclear if the presence of LA without any other potential cerebrovascular disease risk factors significantly increases the risk of cerebral infarction.
NOTE ADDED IN PROOF: After acceptance of this article we encountered 3 additional patients with LA and cerebral ischemia (not included in Tables). A 42-year-old man had a left hemisphere infarct (angiogram normal) followed 2 years later by a left branch retinal artery occlusion (angiogram showed a left ICA occlusion). He was also a heavy smoker with hyperlipidemia. A 30-year-old woman with SLE had recurrent diplopia and alternating monocular vision loss. Angiography demonstrated narrowed ICA and carotid arteries bilaterally. Mitral valve prolapse was also documented. A 66-year-old woman had a 15-minute episode of amnesia, dysarthria, dizziness, and vision loss. She had hypertension and angina. DSA was normal except for tortuous vessels.
Several additional cases in the literature 40^2 have since been identified.
